Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 15/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL868364 | 0.86 | MEN1 (0.53) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL868055 | 0.85 | SLC6A7 (0.58) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL694421 | 0.83 | SLC6A7 (0.74) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL868607 | 0.82 | MGLL (0.49) | ALDH1A1KDM4EMAPTHPGDMGLL | |
| SCHEMBL911909 | 0.78 | SLC6A7 (0.60) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL912559 | 0.78 | SLC6A7 (0.60) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL15703668 | 0.76 | ALDH1A1 (0.76) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL15949476 | 0.76 | HPGD (0.62) | SLC6A7ALDH1A1TSHRMAPK1L3MBTL1 | |
| SCHEMBL867419 | 0.75 | HRH3 (0.46) | ALDH1A1L3MBTL1KDM4EMGLLMEN1 | |
| SCHEMBL868410 | 0.74 | MGLL (0.77) | HPGDMGLL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637498-B2 | Oxopiperazine-azetidine amides and oxodiazepine-azetidine amides as monoacylglycerol lipase inhibitors | JANSSEN PHARMACEUTICA, NV (BE) | 2014-01-28 | — | — | US | disclosed |
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077797-A1 | OXOPIPERAZINE-AZETIDINE AMIDES AND OXODIAZEPINE-AZETIDINE AMIDES AS MONOACYLGLYCEROL LIPASE INHIBITORS | LPL, PNLIP, LIPA | SLC6A7 2817/4885ALDH1A1 624/4885TSHR 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.